North America Conjugate Vaccine Market (2018-2023)
-
Product Code:
RP-ID-10009590 -
Published Date:
21 Oct 2022 -
Region:
Global
-
Pages:
75 -
Category:
Healthcare & Pharmaceuticals -
Publisher:
Pub-ID-13
Impact Analysis on the Growth of Market
Inflation and Looming Recession to Haunt Businesses:
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
....
The Research Report is Updated with 2022 Base Year, 2023 Estimated year and Forecast till 2035 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2022 as base year, 2023 as estimated year and forecast to 2035. This will have market drivers, recovery rate in the market, insights and competitive analysis.
Market Overview:
Translate Report
North America Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%.
Scheduled conjugated vaccinations, have eradicated health disparities and consequently led to lower rate of disease incidence.
Market Segmentation:
o Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics in North America was in the case of DTP vaccines.
o Based on end user, the market is segmented into pediatric and adult.
o Based on countries, the market is divided into U.S. and Canada.
Key growth factors:
North America is projected to be one of the most significant markets for conjugate vaccines during the forecast period, due to a rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Increased diagnosis and treatment are considered to fuel the North American conjugate vaccine market. Recommended vaccines and dosages are updated on a regular basis to comply with prevalent serogroups of infectious agents. For example, the CDC has its own immunization schedule for US citizens. This has increased the effectiveness of administered vaccines, which thereby increases the demand for the product, leading to increase in market sales.
Threats and key players:
o The North America conjugate vaccine market is expected to grow positively. But since it is a saturated market, the scope for significant growth is limited. In North America, the population above 65 years of age has decreased from 53,000,000 in 2014 to 51,900,000 in 2016. So, the demand for adult vaccines has also reduced. The overall penetration rate for the adult segment is lower than that of the pediatric segment.
o Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
What's covered in the report?
1. Overview of the North America conjugate vaccine market
2. Market drivers and challenges in the North America conjugate vaccine market
3. Market trends in the North America conjugate vaccine market
4. Historical, current and forecasted market size data for North America based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) - by revenue and by volume
5. Historical, current and forecasted market size data for North America based on end user (pediatric and adult conjugate vaccines) - by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines by countries (U.S., Canada) - by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments - by revenue and by volume
8. Analysis of the competitive landscape and profiles of major companies operating in the North American market
Why buy?
o Understand the demand for conjugate vaccines to determine the viability of the market
o Understand the country-specific market size and observations for each segment
o Develop strategies based on the drivers, trends and highlights for each of the segments
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
o Recognize the key competitors of this market and respond accordingly
o Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
o Define the competitive positioning by comparing the products and services with the key players in the market
Customizations available
With the given market data, Kenneth Research offers customizations according to specific needs. Write to us at sales@kennethresearch.com.
Geography Analysis:
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
.
Please enter your personal details below
o Pfizer Inc.
o Merck & Co.
o Novartis
o Sanofi Pasteur
o CSL Limited
o Nuron Biotech Inc.